Validation of the DNA damage immune response signature in patients with triple-negative breast cancer from the SWOG 9313c trial by Sharma, P, Barlow, WE, Godwin, AK, Parkes, EE, Knight, LA, Walker, SM, Kennedy, RD, Harkin, DP, Logan, GE, Steele, CJ, Lambe, SM, Badve, S, Gökmen-Polar, Y, Pathak, HB, Isakova, K, Linden, HM, Porter, P, Pusztai, L, Thompson, AM, Tripathy, D, Hortobagyi, GN, Hayes, DF

Molecular subgroup of primary prostate cancer presenting with metastatic biology. by Walker, SM, Knight, LA, McCavigan, AM, Logan, GE, Berge, V, Sherif, A, Pandha, H, Warren, AY, Davidson, C, Uprichard, A, Blayney, JK, Price, B, Jellema, GL, Steele, CJ, Svindland, A, McDade, SS, Eden, CG, Foster, C, Mills, IG, Neal, DE, Mason, MD, Kay, EW, Waugh, DJ, Harkin, DP, Watson, RW, Clarke, NW, Kennedy, RD

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma by Turkington, RC, Knight, LA, Blayney, JK, Secrier, M, Douglas, R, Parkes, EE, Sutton, EK, Stevenson, L, McManus, D, Halliday, S, McCavigan, AM, Logan, GE, Walker, SM, Steele, CJ, Perner, J, Bornschein, J, MacRae, S, Miremadi, A, McCarron, E, McQuaid, S, Arthur, K, James, JA, Eatock, MM, O'Neill, R, Noble, F, Underwood, TJ, Harkin, DP, Salto-Tellez, M, Fitzgerald, RC, Kennedy, RD, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group